Ultraviolet A in vitiligo

El‐Mofty, Medhat; Mostafa, Wedad Z.; Youssef, Randa; Elfangary, Mona M.; El-Ramly, Amany Z.; Mahgoub, Doaa; Fawzy, Marwa M.

doi:10.1111/j.1600-0781.2006.00229.x

Cited by 25 publications

(19 citation statements)

References 2 publications

(2 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…58 PUVA is approved by the FDA for the treatment of vitiligo, 59 but high doses of UVA alone (15 J/cm 2 ) induce repigmentation of more than 60% in half of subjects. 60 Enhanced with psoralen, response rates are as high as 78% and up to 100% for head and neck lesions in more than half of subjects. Lesions on the extremities are less responsive.…”

Section: Phototherapy Key Pointsmentioning

confidence: 98%

Vitiligo: A comprehensive overview

Felsten

Alikhan

Petronic‐Rosic

2011

Journal of the American Academy of Dermatology

151

View full text Add to dashboard Cite

Section: Phototherapy Key Pointsmentioning

confidence: 98%

Vitiligo: A comprehensive overview

Felsten

Alikhan

Petronic‐Rosic

2011

Journal of the American Academy of Dermatology

151

View full text Add to dashboard Cite

“…Long‐wave ultraviolet A1 (UVA1) (340‐400 nm) therapy with low dose [10‐30 Joules (J)/centimeter 2 (cm 2 )], medium dose (40‐70 J/cm 2 ), and high dose (up to 130 J/cm 2 ) has been used since 1981 . UVA1 can penetrate deeper than UVA2 (320‐340 nm) and therefore could reach deeper in the skin dermis . UVA1 has common biological effects with NB‐UVB with almost none of the adverse effects associated with other phototherapeutic modalities.…”

Section: Introductionmentioning

confidence: 99%

The role of long‐wavelength ultraviolet A1 (UVA1) in acral vitiligo

El-Zawahry

Elmasry

Ragab³

2018

J of Cosmetic Dermatology

View full text Add to dashboard Cite

Summary Introduction Acral vitiligo is a resistant subtype of vitiligo that does not respond easily to any treatment modality. Ultraviolet A1 (UVA1) (340‐400 nm) therapy can penetrate the deep dermis of the skin and is relatively free of adverse effects associated with different phototherapeutic modalities. This study's objective was to evaluate the effect of medium‐dose long‐wavelength UVA1 (40‐70 J) in acral vitiligo treatment and compare it with topical psoralen plus ultraviolet A (topical PUVA). Methods Patients in this randomized‐controlled comparative clinical trial were divided into two groups, medium‐dose UVA1 group and topical PUVA group (10 acral vitiligo patients each). Patients received 36 sessions of phototherapy over a period of 12 weeks. Every patient was clinically evaluated monthly as regards the appearance of new lesions or increase in diameter of the current lesion according to point counting and vitiligo area severity index. Results No statistically significant clinical difference was found between patients in UVA1 and topical PUVA groups regarding response and pattern of response (P > 0.05). Conclusion Ultraviolet A1 seems to be of limited use as a monotherapy in acral vitiligo treatment. However, more studies combining it with other treatment modalities as systemic steroids and/or using higher UVA1 doses may prove beneficial.

show abstract

“…The use of BB-UVA alone without the addition of photosensitizers has been attempted in a pilot study [91] that included 20 randomly selected patients with bilateral symmetrical vitiligo involving more than 30% of the body surface area. They were equally divided into two groups and all patients received three weekly sessions of UVA, 15 J/cm 2 in group I and 5 J/cm 2 in group II.…”

Section: Psoralen and Solar Exposurementioning

confidence: 99%

Phototherapy in vitiligo

El‐Mofty¹,

Mostafa²,

Esmat³

et al. 2012

Journal of the Egyptian Womenʼs Dermatologic Society

Self Cite

View full text Add to dashboard Cite

Phototherapy is the backbone of vitiligo treatment. Besides the use of heliotherapy since ancient times, artificial sources have been introduced for the last decades in different wavelengths and administration devices utilizing a multitude of regimens and treatment combinations. In this article, we present a comprehensive compilation of the use of different modalities of phototherapy in vitiligo on the basis of a multitude of related comparative studies that have been carried out during the last decade, including those performed at the Phototherapy Unit, Kasr Al Aini Hospital. The phototherapeutic modality most commonly utilized in the treatment of vitiligo at present is narrowband ultraviolet B (NB-UVB) (311 nm), although in our area, photochemotherapy still continues to be used. Efforts have been made to take into account most comparative studies including the different combinations of NB-UVB with other modalities. The different types of psoralens used in photochemotherapy are discussed, besides comparison of the use of various ultraviolet light sources in vitiligo. The results of studies comparing both psoralen plus ultraviolet A and NB-UVB are also included. A more recently emerging phototherapeutic modality in the treatment of vitiligo and other photoresponsive dermatoses is broadband UVA, which awaits shortterm and long-term safety evaluation studies, both clinical and laboratory. Diverse tools yielding targeted phototherapy are widely being used nowadays in the treatment of vitiligo. Systems range from laser to incoherent pointed light equipment to larger but localized sources, all aiming at sparing the unaffected skin undue radiation exposure.

show abstract

Ultraviolet A in vitiligo

Cited by 25 publications

References 2 publications

Vitiligo: A comprehensive overview

Vitiligo: A comprehensive overview

The role of long‐wavelength ultraviolet A1 (UVA1) in acral vitiligo

Phototherapy in vitiligo

Contact Info

Product

Resources

About